AMPK activation can reduce NAFLD mainly through three ways: inhibiting fat production in liver, increasing fatty acid oxidation in liver and promoting mitochondrial functional integrity in adipose tissue (Smith et al., 2016). This evidence concerns the gene PRKAA1 and metabolic dysfunction-associated steatotic liver disease.